Pro-Soft Val-boroPro: A strategy for enhancing in vivo performance of boronic acid inhibitors of serine proteases

Journal of Medicinal Chemistry

Volumn 54, Issue 7, 2011, Pages 2022-2028

  Poplawski, Sarah E ^a   Lai, Jack H ^a   Sanford, David G ^a   Sudmeier, James L ^a   Wu, Wengen ^a   Bachovchin, William W ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BORONIC ACID DERIVATIVE; CHYMOTRYPSIN A; CYCLOHEXYL(GLYCINYL)PROLINYLVALINYLBOROPROLINE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; PRODRUG; PROLINE IMINOPEPTIDASE; SERINE PROTEINASE; TALABOSTAT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYCLIZATION; DOSE RESPONSE; DRUG ACTIVATION; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PH; RAT; STRUCTURE ACTIVITY RELATION; SURVIVAL;

ANIMALS; BORONIC ACIDS; CYCLIZATION; DIPEPTIDES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; MALE; MICE; PRODRUGS; RATS; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 79953792552     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100972f     Document Type: Article

References (28)

1. Adams, S.; Miller, G. T.; Jesson, M. I.; Wantanabe, T.; Jones, B.; Wallner, B. P. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism Cancer Res. 2004, 64, 5471-5480 (Pubitemid 39006571)
2. Kubota, T.; Flentke, G. R.; Bachovchin, W. W.; Stollar, B. D. Involvement of dipeptidyl peptidase IV in an in vivo immune response Clin. Exp. Immunol. 1992, 89, 192-197
3. Kelly, T. A.; Adams, J.; Bachovchin, W. W.; Barton, R. W.; Campbell, S. J.; Coutts, S. J.; Kennedy, C. A.; Snow, R. J. Immunosuppressive boronic acid dipeptides: correlation between conformation and activity J. Am. Chem. Soc. 1993, 115, 12637-12638 (Pubitemid 24077513)
4. Mentlein, R.; Gallwitz, B.; Schmidt, W. E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7′36) amide, peptide histidine methionine and is responsible for their degradation in human serum Eur. J. Biochem. 1993, 214, 829-835 (Pubitemid 23188160)
5. Kieffer, T. J.; McIntosh, C. H.; Pederson, R. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 1995, 136, 3585-3596
6. Choy, M.; Lam, S. Sitagliptin: a novel drug for the treatment of type 2 diabetes Cardiol. Rev. 2007, 15, 264-271 (Pubitemid 47282035)
7. Traynor, K. FDA approves saxagliptin for type 2 diabetes Am. J. Health Syst. 2009, 66, 1513
8. Croxtall, J. D.; Keam, S. J. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus Drugs 2008, 68, 2387-2409
9. Horie, Y.; Hayashi, N.; Dugi, K.; Takeuchi, M. Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo Trials 2009, 10, 82
10. Pratley, R. E. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes Expert Opin. Pharmacother. 2009, 10, 503-512
11. Connolly, B. A.; Sanford, D. G.; Chiluwal, A. K; Healey, S. E.; Peters, D. E.; Dimare, M. T.; Wu, W.; Liu, Y.; Maw, H.; Zhou, Y.; Li, Y.; Jin, Z.; Sudmeier, J. L.; Lai, J. H.; Bachovchin, W. W. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety J. Med. Chem. 2008, 51, 6005-13
12. Narra, K.; Mullins, S. R.; Lee, H. O.; Strzemkowski-Brun, B.; Magalong, K.; Christiansen, V. J.; McKee, P. A.; Egleston, B.; Cohen, S. J.; Weiner, L. M.; Meropol, N. J.; Cheng, J. D. Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer Cancer Biol. Ther. 2007, 6, 1691-1699 (Pubitemid 351590302)
13. Eager, R. M.; Cunningham, C. C.; Senzer, N. N.; Stephenson, J., Jr.; Anthony, S. P.; O'Day, S. J.; Frenette, G.; Pavlick, A. C.; Jones, B.; Uprichard, M.; Nemunaitis, J. Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma BMC Cancer 2009, 9, 263
14. Eager, R. M.; Cunningham, C. C.; Senzer, N.; Richards, D. A.; Raju, R. N.; Jones, B.; Uprichard, M.; Nemunaitis, J. Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer Clin. Oncol. 2009, 21, 464-472
15. th ASH Annual Meeting and Exposition, 2008, Abstract 2579.
16. Lankas, G. R.; Leiting, B.; Roy, R. S.; Eiermann, G. J.; Beconi, M. G.; Biftu, T.; Chan, C. C.; Edmondson, S.; Feeney, W. P.; He, H.; Ippolito, D. E.; Kim, D.; Lyons, K. A.; Ok, H. O.; Patel, R. A.; Petrov, A. N.; Pryor, K. A.; Qian, X.; Reigle, L.; Woods, A.; Wu, J. K.; Zaller, D.; Zhang, X.; Zhu, L.; Weber, A. E.; Thornberry, N. A. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9 Diabetes 2005, 54, 2988-2994 (Pubitemid 41401097)
17. Feng, J.; Zhang, Z.; Wallace, M. B.; Stafford, J. A.; Kaldor, S. W.; Kassel, D. B.; Navre, M.; Shi, L.; Skene, R. J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D. R.; Gwaltney, S. L. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV J. Med. Chem. 2007, 50, 2297-2300 (Pubitemid 46799241)
18. Coutts, S. J.; Kelly, T. A.; Snow, R. J.; Kennedy, C. A.; Barton, R. W.; Adams, J.; Krolikowski, D. A.; Freeman, D. M.; Campbell, S. J.; Ksiazek, J. F.; Bachovchin, W. W. Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides J. Med. Chem. 1996, 39, 2087-2094
19. Cheng, J. D.; Valianou, M.; Canutescu, A. A.; Jaffe, E. K.; Lee, H. O.; Wang, H.; Lai, J. H.; Bachovchin, W. W.; Weiner, L. M. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth Mol. Cancer Ther. 2005, 4, 351-360 (Pubitemid 40443920)
20. Santos, A. M.; Jung, J.; Aziz, N.; Kissil, J. L.; Puré, E. Targeting fibroblast activation protein inhibitor tumor stromagenesis and growth in mice J. Clin. Invest 2009, 119, 3613-3625
21. Jesson, M. I.; McLean, P. A.; Miller, G. T.; Adams, S.; Aubin, J.; Jones, B. Immune mechanism of action of talabostat: a dipeptidyl peptidase targeted antitumor agent. In Proceedings of the 98th Annual Meeting of the American Association for Cancer Research, 2007, Abstract 1894.
22. Burkey, B. F.; Hoffmann, P. K.; Hassiepen, U.; Trappe, J.; Juedes, M.; Foley, J. E. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited Diabetes Obes. Metab. 2008, 10, 1057-1061
23. Wu, J.; Tang, H.; Yeh, T.; Chen, C.; Shy, H.; Chu, Y.; Chien, C.; Tsai, T.; Huang, Y.; Huang, Y.; Huang, C.; Tseng, H.; Jiaang, W.; Chao, Y.; Chen, X. Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor Biochem. Pharmacol. 2009, 78, 203-210
24. Snow, R. J.; Bachovchin, W. W.; Barton, R. W.; Campbell, S. J.; Coutts, S. J.; Freeman, D. M.; Gutheil, W. G.; Kelly, T. A.; Kennedy, C. A. Studies on proline boronic acid dipeptide inhibitors of dipeptidyl peptidase IV: identification of a cyclic species containing a B-N bond J. Am. Chem. Soc. 1994, 116, 10860-10869
25. Bodor, N.; Buchwald, P. Soft drug design: general principles and recent applications Med. Res. Rev. 2000, 20, 58-101 (Pubitemid 30027561)
26. Pao, L.; Hsiong, C.; Hu, O. Y.; Wang, J.; Ho, S. In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine Drug Metab. Dispos. 2005, 33, 395-402 (Pubitemid 40279940)
27. Kane, R. C.; Farrell, R. T.; Sridhara, R.; Pazdur, R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy Clin. Cancer Res. 2006, 12, 2955-2960 (Pubitemid 43837337)
28. Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A.; Pierres, M.; Nielsen, P. F.; Ribel, U.; Watanabe, T.; Drucker, D. J.; Wagtmann, N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 6874-6879 (Pubitemid 30412807)